TRIESENCE Drug Patent Profile

When do Triesence patents expire, and when can generic versions of Triesence launch?

Triesence is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Triesence

A generic version of TRIESENCE was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for TRIESENCE

International Patents:	25
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	11
Patent Applications:	4,809
Drug Prices:	Drug price information for TRIESENCE
What excipients (inactive ingredients) are in TRIESENCE?	TRIESENCE excipients list
DailyMed Link:	TRIESENCE at DailyMed

See drug prices for TRIESENCE

Recent Clinical Trials for TRIESENCE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Research Insight LLC	PHASE4
Oxular Limited	Phase 2
Wake Forest University Health Sciences	Phase 4

See all TRIESENCE clinical trials

Pharmacology for TRIESENCE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for TRIESENCE

TRIESENCE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007		RX	Yes	Yes
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007		RX	Yes	Yes			Y

Expired US Patents for TRIESENCE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007

International Patents for TRIESENCE

See the table below for patents covering TRIESENCE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009114521
Taiwan	200940071	Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
South Korea	20100127267
Argentina	070824
Brazil	PI0909630
Slovenia	2262506

TRIESENCE (triamcinolone acetonide injectable): Market dynamics and financial trajectory

Last updated: April 25, 2026

TRIESENCE is an ophthalmic corticosteroid for intraocular use, authorized for treating inflammation. Commercial performance depends on (1) ophthalmology procedure volumes, (2) adoption of competing intraocular anti-inflammatory and anti-VEGF regimens, (3) pricing and contracting in private and government payor channels, and (4) patent and exclusivity status that shapes generic and biosimilar pressure in the US and ex-US markets.

How big is the commercial opportunity for TRIESENCE?

TRIESENCE is positioned inside retina and uveitis-linked treatment pathways, where physicians use corticosteroids to control inflammation and macular edema. Demand tracks closely to:

• Patient volumes entering ophthalmology clinics for inflammatory conditions and macular edema treatment.
• Use rates of intravitreal or periocular injection procedures.
• Treatment strategy mix versus anti-VEGF and combination regimens.

Market linkage

• Retina-driven procedure demand: Intravitreal injection counts are a core demand driver across ophthalmology. When injection volumes rise, corticosteroid share can rise or fall based on clinical preference and payor reimbursement.
• Inflammation management mix: Corticosteroids compete with non-steroidal anti-inflammatory approaches and with anti-VEGF regimens when edema is driven by vascular pathology rather than pure inflammation.

What pricing and contracting mechanics shape TRIESENCE revenue?

In ophthalmology, price is typically set and negotiated through:

• Wholesale acquisition cost (WAC) and subsequent rebates in commercial contracts.
• Medicaid and Medicare reimbursement rules in the US.
• Tender and national reimbursement schedules in EU markets.
• Patient access programs and institutional contracting for high-volume clinics.

Commercial pricing pressure channels

• Formulary steering: Managed care formularies determine whether a drug remains a “preferred” option for ophthalmologists.
• Step edits and prior authorization: Common for higher-cost ophthalmic injectables, especially when used off-label.
• Shorter treatment cycles and alternative standards of care: If prescribers switch to anti-VEGF first-line and reserve steroids later, corticosteroid spend grows more slowly even when procedure volumes rise.

Which competitive classes pressure TRIESENCE demand?

TRIESENCE competes in a crowded ophthalmic injectable landscape, where therapeutic substitution is clinically plausible.

Main competitive pressure vectors

• Anti-VEGF injections (for macular edema due to vascular causes): These often anchor treatment algorithms, limiting steroid share.
• Other intravitreal or periocular steroids: Compounds with longer duration or lower re-treatment frequency can displace steroids with shorter effective windows.
• Surgical and procedural alternatives: In inflammatory pathways, procedural timing can affect steroid injection frequency.
• Non-steroidal approaches in select indications: Depending on clinical context, these may reduce steroid utilization.

How do exclusivity, patent, and generics affect TRIESENCE financial trajectory?

Financial trajectory in this class is commonly dominated by the interaction of:

• Patent life and exclusivity expiration (US and major ex-US geographies).
• Generic entry timing and label/brand switching.
• Interchangeability in practice: Even when a generic exists, ophthalmologists may resist switching if dosing and suspension characteristics differ.

What to watch in the financial pattern

• Revenue peaks typically occur before exclusivity expires.
• Post-expiry periods show steeper erosion when multiple competitors enter and formulary inclusion shifts to lower-cost alternatives.
• Trajectory stabilizes only after payer contracting normalizes and supply catches up.

How do procedure volumes and clinical guidelines drive TRIESENCE utilization?

TRIESENCE usage is sensitive to practice patterns:

• Injection frequency: Steroid injections typically require repeat dosing more often than long-acting steroid depots in some clinical scenarios.
• Disease course: Chronic inflammation and recurrent macular edema increase repeat dosing, but only if prescribers remain on steroid strategies.
• Steroid risk management: Increased intraocular pressure and cataract risk can limit repeat steroid exposure, pushing prescribers toward alternatives when feasible.

What should you infer about TRIESENCE revenue trend from ophthalmic market structure?

For ophthalmic injectables, revenue generally follows:

1. Adoption phase: Gradual uptake when outcomes and clinician confidence increase.
2. Mature phase: Growth slows as treatment algorithms standardize.
3. Share shifts: Anti-VEGF dominance, steroid depot preferences, and formulary changes can reduce share even if total injections rise.
4. Loss of exclusivity: Generic/biosimilar-like competitive effects (for small-molecule generics) trigger fast revenue declines in the US and slower erosion abroad depending on reimbursement rigidity.

What does the financial trajectory look like across US vs ex-US markets?

TRIESENCE’s international trajectory typically depends on reimbursement frameworks:

• US: Faster competitive response to generic entry and aggressive formulary contracting.
• EU: Longer reimbursement cycles can delay immediate price erosion but can also lock in lower prices once national decisions occur.
• Emerging markets: Procurement volatility and distributor networks can produce uneven quarter-to-quarter performance, but long-run demand aligns with procedure volumes and payor access.

What are the key “leading indicators” for TRIESENCE sales going forward?

These factors typically move before headline sales do:

• Intravitreal injection counts and retina clinic throughput.
• Formulary and prior authorization policy changes at major payors.
• Conversion trends from steroids toward depot steroids or anti-VEGF-first approaches.
• Generic penetration and switching behavior after exclusivity events.
• Supply continuity and packaging availability that affects clinic purchasing behavior.

How does investor and operator diligence translate into a financial model for TRIESENCE?

A practical financial model for TRIESENCE should represent:

• Volume: Treated patient counts and number of injections per treated patient.
• Price: Net price after rebates and contract concessions, with distinct US vs ex-US assumptions.
• Share: TRIESENCE’s share within steroid-relevant sub-pathways (inflammation-mediated edema, uveitis-linked use, steroid-sparing strategies).
• Competition: Annual share changes tied to competitor launches, depot shifts, and generic entries.
• Timing: Place losses of exclusivity and generic introductions on a calendar basis to capture steep post-entry revenue steps.

Revenue decomposition template (annual)

Component	Definition for TRIESENCE	Directional risk
Unit volume	Injections dispensed	Down with guideline-driven substitution
Net price	After rebates and contracting	Down with formulary pressure and generics
Market share	Share in steroid-injection subset	Down with competing longer-acting agents
Mix	Indication and severity mix	Shifts with clinician selection
Competition events	Generic entry, depot preference, tender outcomes	Drives step-function changes

What is the most likely financial trajectory pattern for TRIESENCE?

Given the ophthalmology market structure, a common trajectory is:

• Stable-to-moderate growth during early adoption and niche dominance in specific inflammatory pathways.
• Slower growth in maturity as anti-VEGF regimens dominate macular edema treatment algorithms.
• Step-down or accelerated erosion in periods of exclusivity loss and generic entry, moderated by clinical switching resistance and reimbursement specifics.

Key Takeaways

• TRIESENCE demand is driven by ophthalmology procedure volumes and the share of treatment pathways that still use corticosteroid injections versus anti-VEGF-first and depot steroid-first strategies.
• Net revenue is shaped more by contracting and reimbursement dynamics than by WAC alone, with rebates, prior authorization, and formulary steering determining realized pricing.
• The financial trajectory is most likely to follow a maturity-and-substitution path, with revenue erosion concentrated around exclusivity windows and generic or alternative product penetration.
• A robust financial model should separate volume, net price, share, mix, and time-based competition events to capture step changes rather than smooth trends.

FAQs

1. What drives TRIESENCE sales most directly?
   Ophthalmology procedure volumes and the fraction of treated macular edema or inflammation cases where corticosteroid injections remain the chosen strategy.

2. How do anti-VEGF therapies affect TRIESENCE?
   Anti-VEGF regimens often anchor macular edema algorithms, which can limit steroid share even when injection volumes rise overall.

3. What determines how fast revenue falls after generic entry?
   Formulary placement, rebate intensity, and real-world switching behavior among ophthalmologists, plus reimbursement rules across major payors.

4. Why can steroid risk management limit repeat dosing?
   Clinical concerns such as intraocular pressure elevation and cataract risk can reduce the willingness to continue repeated steroid injections.

5. What metrics best forecast TRIESENCE’s next 4 to 8 quarters?
   Retina clinic injection counts, payor formulary and prior authorization changes, competitor share shifts (anti-VEGF and depot steroids), and the timing of exclusivity and entry events.

---

References

[1] U.S. Food and Drug Administration. “Drug Trial Snapshots: TRIESENCE.” FDA. https://www.fda.gov/ (accessed 2026-04-25).
[2] U.S. FDA. Prescribing Information for TRIESENCE (triamcinolone acetonide injectable). FDA access system. https://www.accessdata.fda.gov/ (accessed 2026-04-25).